text:
What really grinds my gears? Episode 11 - The Next Generation
by, 08-01-2013 at 10:53 AM (3080 Views)
"Episode 11?? I thought we finished this garbage on the last episode?"
"No Mr Griffin, we just didn't have anymore material to give you."
"What are you talking about? I could complain about wrestling all day! I demand to see the guy in charge!"
"I am the guy in charge, and you sir, are an idiot."
"Oh .. well I may be an idiot, but there is one thing I am not, sir, and that sir, is an idiot."
"Umm ... err ... get on with it?"
"Grinds my gears when you make me do stuff."
Episode 11 - The Next Generation
A long time ago, back in ancient times (around January), the blog series came to an abrupt end at the 10th episode. However, due to .. let's say pure boredom? I have decided to bring it back. You could even say I am bringing it back like Star Trek brought out The Next Generation, all improved with a new spaceship, crew, and played by much better actors.
However this blog, as much as I love sci-fi and comedy, is all about wrestling and the next generation of wrestlers and fans.
So why does the next generation grind my gears so? Why do I feel the need to make a blog about something that has not happened yet?
I am deeply concerned that's why. It feels like people don't know what is cool anymore, and they continue to be fed the same old mediocre garbage that even a hoarder wouldn't want.
On my last blog I touched on the subject of broken dreams. How many wrestlers of the past and present failed to live up to their true potential. This is still apparent in some cases, however I have an update.
Dolph Ziggler finally became World Champion, only to lose it to Del Rio not long after. He has still not received his much deserved break as a top competitor, and this worries me. However Daniel Bryan is breaking out as a top star that could rival Cena. I am sure Vince has no idea how to talk down Daniel Bryan, this was evident by the abysmal promo he did on Raw lately.
On the other side of the spectrum, Chris Sabin became the TNA World Heavyweight Champion. This victory should have been a victory for TNA and all of their fans, and a step in the right direction .. except all I see is negativity over his victory.
Fans saying things like "Sabin does not deserve it.", "Sabin is too small, he is a mid carder at best", "Sabin sucks on the mic", "Sabin will lose the title soon."
There are many problems with the title change.
1) Chris Sabin was at his most popular during the golden age of TNA, as he took the X-Division by storm, if there was any time to put the strap on him, it was during the period where guys like AJ Styles and Jeff Jarrett were holding onto it.
2) Lack of build. - After almost two years out, he came back and never really got past the "I tore both my ACLs and came back" comeback story, which tells us this title change could have been more out of sympathy and a feeling of owing Sabin for his many years of service to TNA.
3) An afterthought - With Aces and Eights running wild (brother), Hogan continuing to take up space, and Main Event Mafia returning, the emphasis was never on Chris Sabin. Even more so, Austin Aries took the title off him, which took even more emphasis off Sabin. Although Hogan "endorsed" Sabin as the next World Champion, who really thought in their head "Oh wow Hogan is singing his praises, he must be awesome!". Anyone who really knows of Sabins work knows just how talented he is as an athlete.
4) The match itself - Let's be honest, it was terrible. It was on free tv, and Sabin got beat on throughout the whole match. MEM and A&8s being around ringside took all the spotlight off Sabin, and it just felt like Sabin was a small pawn in the huge chess game that is the gang warfare going on right now. Also he beat Bully Ray with his own trademark of using the hammer, something which Chris Sabin never does. Sabin has always been a full on good guy, he never cheats to win, and to win his first world title by using a hammer told us that he apparently wasn't good enough to beat him without cheating.
Don't get me wrong! Sabin being World Champion is a good thing! However they didn't do it in the right way, and it should have been a much bigger shock to the world.
Onto the current world champions, you see guys like Cena and Del Rio hold the titles, despite not being unanimously liked/hated/cared about and that worries me. In the past, champions were either extremely liked, or extremely hated by all, and that is what made great television. Can you name any WWF Champions during the attitude era that had a mixed reaction?
And onto the attitude era, people still look back on the Attitude era as the greatest time in the business, and it probably always will be, specially with how society is today. There are so many rules and spotlight on the business now. There is also a pure lack of proper promo time. Having watched some older promos today, there is a severe lack of passion and intensity in the business today.
What happened? Will we ever see promos like these again? Somehow I doubt it. It all seems rather bleak from here on out. However we do have some hopes.
In the WWE, Daniel Bryan, Ziggler, The Shield, Damien Sandow and maybe Bray Wyatt stick out to me as potential future main eventers. Cena is getting older now, it just depends how long he wants to hold onto his spot as "The Man", and hopefully he won't be replaced by Ryback. Ryback is somewhat decent, but he seems like that typical guy that Vince would shove down our throats if he starts selling merchandise at a decent rate. Totally wouldn't mind Ryback being a top heel though, someone of his size can make smaller guys like Ziggler and Bryan look even greater then they already are.
The biggest factors with the future all come down to Vince McMahon and Dixie Carter however. Will Vince step down and let Triple H and Stephanie run the ship? Will Dixie stop bringing in guys like Rampage Jackson and bring us the TNA of the golden era again?
Who knows. All I do know is that I am tired of the same old faces at the top. Wrestling in general needs to shake things up a bit, and do it in such a way which is cool and refreshing, instead of doing it just for short time shock value.
What worries me even more is the fan base. Those kids who have grown up watching Cena will only have heard of the Attitude and Golden eras, and will only see "Sports Entertainment" as it is now, with no real comparison to what "Wrestling" was about. It worries me that people will one day say "Hull Kogan who?" and even worse, "Who is Stone Cold Steve Austin???".
Can you imagine it? Adults saying they have no clue who Steve Austin is?? Can you see why this grinds my gears?? People need to educate these kids and quick before all is lost.
I am going to round this up. Do you think the wrestling business has a bright future? Or will it only end up spiraling down into obscurity? Maybe doing so might make it better in the long term?
Until next time! You crazy people.


text:
It was the semi-finals on "Dancing With the Stars" All-Star Season 15, and we were down to a battle between the five best celebrity dancers and their partners. Unfortunately, the sixth good dancer (Gilles Marini) was eliminated last week, and the seventh (Sabrina Bryan) went home in Week 6. Now, it will be up to who dances the best ... and who has the strongest fan base.
Tonight, the couples first had to perform a dance -- a weird mix of theme and style -- that they had never done before and was chosen by another couple. For their second appearance, the dancers paid tribute to Michael Jackson's "BAD" album on its 25th anniversary ... which just so happens to be featured in an ABC special Thanksgiving night. Each of the couples danced to a song from the album, with Jackson's mom sitting in the front row of the audience.
None of the celebrity dancers copied the title of Jackson's album and instead of being "bad," they were determined to be the best they could be. Shawn Johnson and Derek Hough climbed back to the top spot on the leaderboard with a "Knight Rider" bhangra (Indian folk dance) that was more Bollywood than Hasselhoff, but received raves from the judges and a lengthy standing ovation from the audience. After giving Shawn a big hug, judge Bruno Tonioli called it "another hit and this time, they did it bhangra-style!" Judge Carrie Ann Inaba observed that Shawn was "finally out of breath," then head judge Len Goodman, usually very conservative and restrained, shouted, "Shut up! Close the door! Call me Mary! This was fantastic!" Their second dance was an Argentine tango to "Bad," and it was "baaaad" in a very good way. Bruno said it was "breath-taking," Len said they "nailed it," but although she said "every line was perfection," Carrie Ann thought it lacked passion. And only a score of 9 from Carrie Ann denied them two triple-10's.
Only one and a half points behind the leaders were Melissa Rycroft and Tony Dovolani, who ruled the leaderboard last week, but first there was more drama and an injury update on Tony. During rehearsal, he pulled something in his back and was flat-out on the dance floor. Host Tom Bergeron announced that Tony had been cleared to dance, but noticing the couple's costumes for their "Caveman" hustle, he added that it may have "impacted (Tony's) fashion sense." The pair took one of the strangest combinations and made a huge success of it. "Fred and Wilma never danced so well. Melissa had the hustle, Tony had the muscle," said Len. He added that they "captured the flavor of the caveman," at which Tom asked, "Does that come up often in dance?" However, both Bruno and Carrie Ann noted that the dancers lost their footing and balance at times. Their choice from the "BAD" album was "Dirty Diana" and they did an Argentine tango that was very different from Shawn and Derek's. Bruno said the "sequence of lifts was absolutely extraordinary," and I agree -- I need to go back and watch that dance again, and maybe one more time. As Carrie Ann said, "'Dirty Diana' meet Magnificent Melissa -- those lifts were out of this freaking world!"
The third couple to perform the weird-mix dance was Apolo Anton Ohno and Karina Smirnoff, who had the unfortunate luck to be assigned "Big Top" jazz. They were really trying but it just didn't do much for me. It was a bit sloppy and Apolo even had a slip in the opening steps. The judges described it as "disjointed" and with "a couple of awkward moments," but Bruno really liked it, saying it was a combination of "Cirque du Soleil" and "Clockwork Orange" and that it was "excellent." In their second dance, if they planned to leave a lasting memory of a winning dance with the viewers, Apolo and Karina managed it in their sexy, sensuous rumba to "Man in the Mirror." It was so sizzling, heat waves seem to shimmer off the pair. Carrie Ann pointed out that "you don't have to over-dance to achieve perfection. You reached into my heart and melted it," and Len said, "It was wave after wave of effortless motion." If that dance is all the voting viewers remember, the pair will be in next week's finals.
Emmitt Smith and Cheryl Burke took their mixed dance, "Espionage" Lindy hop, and had a lot of fun dancing well. As a bad spy and a good spy, the couple put a cartoon-ish spin on it that had Bruno calling it "a Looney Tunes version of James Bond," while Carrie Ann told Emmitt that it was "the most animated performance I've seen." Len said the whole package was excellent but needed a little more Lindy hop. Then, dancing a traditional tango to "Leave Me Alone" in matching burgundy outfits, the pair received generally admiring comments from the judges. "In both routines (you did tonight), you really brought your 'A' game. However, your hold was a bit broad," said Carrie Ann, being kinda picky.
Kelly Monaco and Val Chmerkovskiy, the fifth and final couple to compete, tackled a "Surfer" flamenco that was more paso doble than flamenco, but which really won over the audience and had them screaming long after the dance was done. Since it ended with Kelly in a swimsuit and Val in a Speedo, splashing their way through dance steps in a shallow pool, I don't know whether the screams were for their routine or their outfits. Len said they "went 'all in' with verve and attack," but Bruno said the placement and hand motions weren't there for flamenco. If the pair were all wet for the first dance, the heat generated by their rumba to "I Can't Stop Loving You" dried them off quickly. Bruno called it "smoldering, driven by desire, wonderful," Len said it had "controlled emotion, the light and shade were fantastic," and Carrie Ann pointed out the "honest vulnerability." In addition, at the dance's end, the lights went down and the two, who are rumored to be more than just dance partners, locked in a passionate kiss. Wow!
Now it's up to the voting viewers to add their points to those of the judges, and Tuesday night's results show will end in a double elimination, sending the remaining three couples to the finals Nov. 26. The hourlong show tomorrow night will feature a Macy's "Stars of Dance" performance by Paula Abdul, and a medley sung by The Wanted. Also, Parris Goebel, a self-taught dancer from New Zealand, will do her "polyswagg"-type hip hop in the AT&T Spotlight Dance. Who do you think should advance to the finals next week?
Celebrities and combined scores (mixed dance + dance to Michael Jackson song = total):
Shawn & Derek (Knight Rider/bhangra): Carrie Ann, 10; Len, 10; Bruno, 10 = 30 + (Argentine tango) 9; 10; 10 = 29; total of 59
Melissa & Tony (Caveman/hustle) -- 9; 9.5; 9 = 27.5; (Argentine tango) 10; 10; 10 = 30; total of 57.5
Apolo & Karina (Big Top/jazz) -- 8.5; 9; 9.5 = 27; (rumba) 10; 10; 10 = 30; total of 57
Kelly & Val (Surfer/flamenco) -- 8; 9; 8.5 = 25.5; (rumba) 9.5; 9.5; 9.5 = 28.5; total of 54
Emmitt & Cheryl (Espionage/Lindy hop) -- 9; 9; 9 = 27; (tango) 9; 9; 9 = 27; total of 54

subset: commoncrawl


text:
Kubel's ankle fine in Minor League test
SCOTTSDALE, Ariz. -- D-backs outfielder Jason Kubel played in a Minor League game Wednesday and pronounced his left ankle good to go.
Fellow outfielder Cody Ross, who is expected to begin the year on the disabled list with a lower leg strain, also hit in the game, but did not run the bases.
Kubel twisted his ankle coming out of the batter's box in Tuesday night's game and had to be removed.
Kubel went 4-for-7 in the Minor League game with a pair of home runs and he ran the bases to test the ankle.
"I ran them a little easy and then realized it was feeling pretty good and started running more and felt pretty good," Kubel said.
The spring has been a struggle for Kubel, who is hitting just .150 and has had to deal with a sore knee and then the ankle.
"It felt good to hit some balls," Kubel said Wednesday. "It definitely helps to get as many at-bats as you can. I think today helps with confidence a little bit. I'm just hopefully looking forward to getting the next couple of days out of here healthy. I've been battling things all spring so hopefully everything starts feeling good and stays that way."
Steve Gilbert is a reporter for MLB.com. Follow him on Twitter @SteveGilbertMLB. This story was not subject to the approval of Major League Baseball or its clubs.


text:
A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
|Essential Tremor
|Drug: topiramate
|Phase 3
|Study Type:
|Study Design:
|Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
|Official Title:
|A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Essential Tremor
- Clinical Rating Scale for Tremor (TRS) score at Visit 8 (or patient's final visit) of the double-blind phase
- TRS subscale scores; composite normalized score; overall TRS score; patient and investigator assessment scores.
|Study Start Date:
|October 2001
|Study Completion Date:
|February 2004
Essential tremor is a very common form of tremor, occurring in up to 5% of people. It may be inherited. In 90% of patients, the tremor is in the hands; however, it can also be in the head, voice, legs, jaw, and tongue. Essential tremor may be treated by the blood pressure medicine propranolol or the anti-seizure drug primidone. The drawbacks of these drugs are that they tend to lose effectiveness over time, and they may cause side effects. Researchers believe that topiramate, an anti-seizure drug, may be effective in treating essential tremor. In this double blind, placebo-controlled study, patients with essential tremor will start at a low dose of topiramate (25 milligrams) or placebo. The dose will be gradually increased over 12 weeks to a maximum of 400 milligrams daily, taken in two divided doses. Then, each patient will stay on the established dose for the next 12 weeks. During the next phase of the study, the patients will slowly reduce the dose until they stop taking the study drug, after which, patients have the option of taking up to 600 milligrams of topiramate (not placebo) in a 14-week extension of the study. This study was designed to investigate the hypothesis that topiramate will be more effective than placebo in the treatment of essential tremor as measured by the Clinical Rating Scale for Tremor (TRS) and is well tolerated. The TRS is a three part scale that measures tremor location/severity rating, specific motor tasks/function rating, and functional disabilities resulting from tremor. Safety evaluations are assessed throughout the study.
Topiramate or placebo, starting with a dose of 25 mg, then gradually increased over 12 weeks up to 400 mg daily (two 100-mg tablets taken by mouth twice a day) and continued on this dose for 12 weeks in the maintenance phase; up to 600 milligrams of topiramate in the open-label phase.
|Ages Eligible for Study:
|18 Years to 80 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Current symptoms of essential tremor based on the Tremor Investigational Group (TRIG) criteria
- Dominant upper extremity posture or action intention tremor of 2 (moderate) to 4 (severe)
- In good health otherwise
Exclusion Criteria:
- Patients with abnormal neurologic signs other than essential tremor
- Taking more than one anti-tremor medication
- Taking drugs known to cause tremors
- With physical damage to the nervous system or Parkinson's disease
- Known to be abusing drugs or alcohol
- Women who are pregnant or breast-feeding
Please refer to this study by its ClinicalTrials.gov identifier: NCT00236496
|Study Director:
|Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial
|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Additional Information:
|ClinicalTrials.gov Identifier:
|NCT00236496 History of Changes
|Other Study ID Numbers:
|Study First Received:
|October 7, 2005
|Last Updated:
|June 8, 2011
Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
essential tremor
Additional relevant MeSH terms:
Essential Tremor
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Movement Disorders
Central Nervous System Diseases
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Anti-Obesity Agents
ClinicalTrials.gov processed this record on September 21, 2017


text:
What do you need a range for? Just do like Twes and pick drifters off of I-65.....
'); var yuipath = 'clientscript/yui'; var yuicombopath = ''; var remoteyui = false; } else // Load Rest of YUI remotely (where possible) { var yuipath = 'http://yui.yahooapis.com/2.9.0/build'; var yuicombopath = 'http://yui.yahooapis.com/combo'; var remoteyui = true; if (!yuicombopath) { document.write('
What do you need a range for? Just do like Twes and pick drifters off of I-65.....
Twes is the master. Maybe I could do the same thing off of 37.......
I'm just sayin.
Kind of a tough season for the Geezer.
Michigan fan.
Oh well.
He'll be hittin the Beam
Michigan needs a QB to fit ole Rodriguez's system. That Threet dude is certainly not the answer. It would help if they could just hold the ball without dropping it too.
Shut up.
Geezer whittled arrows run $108 per dozen. That's 6 with field tips and six whittled for broadheads. Flint napped arrowheads are $360/6.
Now I've never actually done any of that stuff...but if you'll pay those prices I'll sure as hell learn. (well I've done it but only for myself)
Ever notice how friendly folks are at a shootin' range??.
Big Green Bay vs Dallas game this weekend aye.
I sense that you're a little upset.
Where is that one at? If it's at Lambeau it should be good times.
Twes, I don't think we'll be getting any freebie arrows anytime soon.
I'll have to let the carbon arrows fly.
It's a night game. I bet it starts after geezer's bed time.
I'm just sayin
Catch the fever.
I need some air freshener for my office.
I have some custom made arrows that I ordered two years ago. I'm thinking they're prolly warped now. They're still taped together with the original masking tape they came in. Never been unwrapped.
I really need a place to shoot.
Hmmmm a church parking lot might just do the trick.
Ever notice how friendly folks are at a shootin' range??.
I once had a compound bow with an overdraw on it (that allowed me to use very short arrows). I was shooting with my bro-in-law getting ready for the season. This one particular shot kinda became a hand grenade in the mess hall situation. I drew back on the bow and the arrow did this funny little flip-flop and became wedged between the bowstring and the bow face. The longer I held the bow the more that aluminum arrow bent. We just knew that at any second that sucker was gonna shatter and "shrapnel" would be flung everywhere.
I flung that sucker to the side and it went off in his swimming pool doing no damage to anyone or anything.
I kid not, I was shakin' after that.
Ever notice how friendly folks are at a shootin' range??.
Did you have a broadhead on that sucker?
That would scare the fark outta me too.
You ever feel like it's just your time.
If it ain't happened in his first 153 years, it ain't gonna get him anytime soon.....


text:
Perhaps the only thing in business more painful than looking for a job is finding someone to fill a position. Getting hired is hard, but hiring can be even worse. It's normally easier for an applicant to know what they're getting into when applying for a job than for the business to know what they're getting when looking at people.
Social media can help.
Continue reading


text:
More articles
More webinars
More events
Formally the NECA Safety Expert System, this online subscription provides users with complete company safety manual, written programs, polices, procedures and forms. Additional features include an industry practices database, NFPA 70E PPE Selector, message board, training materials and a robust recordkeeping system.
Visit the NECA Store
National Electrical Contractors Association - NECA
Like us on Facebook
View our Flickr Photostream
Come network with NECA, a nonprofit membership association founded in 1901 to foster trade and reform abuses within the electrical contracting industry.
Join us on LinkedIn
More YouTube Videos
National Electrical Contractors Association 3 Bethesda Metro Center, Suite 1100 Bethesda, MD 20814 Phone: (301) 657-3110 Fax: (301) 215-4500 Contact NECA Webmaster
© 1995–2012 National Electrical Contractors Association. All rights reserved.
Association Web Design and Development by Matrix Group International, Inc. ®


text:
Full data for both trials will be provided by Omthera's management team at a presentation being held this morning, November 5, 2012 at 7:30 a.m. PST at the Millennium Biltmore Hotel in Los Angeles and also available via live webcast. The webcast and replay of the event will both be available at www.Omthera.com.
Commenting on the positive results of these Phase 3 trials, Michael Davidson, MD, Chief Medical Officer and Co-Founder of Omthera, stated, "We are delighted by the wide-ranging lipid benefits shown by Epanova in both the EVOLVE and ESPRIT trials. Most notably, we are highly encouraged by the strong efficacy demonstrated by the 2 gram dose in significantly lowering triglycerides and Non-HDL-C, as well as established markers of cardiovascular risk for patients taking Epanova either as a monotherapy or in combination with statins."
John J. P. Kastelein, M.D., Ph.D., FESC, Professor of Medicine, Department of Vascular Medicine at the Academic Medical Center, University of Amsterdam, stated, "Epanova's 2 gram dose efficacy for triglyceride, non-HDL-C and ApoC-III reduction provides an effective and well tolerated therapy for an important unmet medical need in patients at high cardiovascular risk due to high triglycerides. With a low starting dose, lack of food effect, and once-a-day dosing that can be readily combined with a statin, Epanova represents a significant improvement over existing prescription Omega-3 therapies. I believe that, if approved, Epanova will be the best-in-class Omega-3 prescription product."
The EVOLVE trial, a 12 week, multi-center, randomized, double-blind study of 399 patients, evaluated the efficacy and safety of three doses of Epanova in patients with fasting TG levels of at least 500 mg/dL but less than 2000 mg/dL. Patients were randomized into four dosing groups: Epanova 2g/day; Epanova 3g/day; Epanova 4g/day; and control (olive oil 4g/day). The study reached its primary endpoint of TG reduction (measured as a percentage change from baseline to week 12) as well as its secondary endpoint of Non-HDL-C at all doses. Specifically, Epanova:
ESPRIT, a six-week, randomized, double-blind, parallel group study of 647 patients, assessed the efficacy and safety of add-on Epanova to statin therapy in patients with persistent hypertriglyceridemia and high risk for cardiovascular disease. Patients were randomized into three dosing groups; Epanova 2g/day; Epanova 4g/day; and control (olive oil 4 g/day). The study met its primary endpoint, a percentage change in Non-HDL-C from baseline to week 6, as well as its secondary endpoints, including a percent change in TG and HDL-C from baseline to week 6.
Specifically, the study showed that Epanova (2g or 4g daily), when added to statin monotherapy:
Jerry Wisler, Chief Executive and Co-Founder of Omthera, added, "Four million patients in the U.S. currently suffer with severely high triglycerides and 40 million patients have high triglycerides, and this population is rapidly increasing. The ability to potentially take a once-a-day 2 gram dose, with or without meals, versus other prescription Omega-3s currently approved by the FDA, which do not offer these dosing options, would represent a tremendous advantage. The data from the EVOLVE and ESPRIT trials underscores our belief that, ultimately, Epanova will become the best-in-class, most convenient prescription Omega-3 on the market. With this data, we look forward to submitting Epanova for approval to the FDA."
About EpanovaEpanova is a patent protected, novel, ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omthera has developed a substantial body of data on Epanova, which points to an improved and more predictable bioavailability as compared to the ethyl ester form found in prescription Omega3 products currently available. Triglyceride lowering with Epanova was previously observed in two large, placebo-controlled, randomized, double-blind, Phase III studies involving 748 Crohn's disease patients with normal triglyceride levels for greater than or equal to 52 weeks, approximately 400 of which were treated with Epanova for remission of disease. In all studies performed to date, Epanova has demonstrated a very good safety and tolerability profile.
About HypertriglyceridemiaHypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and is associated with increased risk of heart disease. It is one component of a range of lipid disorders collectively referred to as dyslipidemia. The overall dyslipidemia population in the U.S. is believed to be in excess of 100 million, with approximately 40 million of those diagnosed with hypertriglyceridemia (triglycerides greater than 200mg/dL) and an estimated 4 million with very high triglyceride levels (triglycerides greater than 500mg/dL). Very high triglycerides are associated with an increased risk of pancreatitis. Regulatory approval for the treatment of very high triglycerides is based on a significant reduction in the serum triglyceride levels.
About Omthera Pharmaceuticals, Inc.Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately held, specialty pharmaceutical company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product. For more information, please visit www.omthera.com.
Omthera Contact:
Christian Schade
Chief Financial Officer
Omthera Pharmaceuticals
Omthera Media Relations:
Eric Goldman
Vice President Public Relations
Rx Communications Group, LLC
SOURCE Omthera Pharmaceuticals, Inc.


text:
This quote is hidden because you are ignoring this member. Show Quote
Yeah it is.
Cavs fans are the big loser.
'); var yuipath = 'clientscript/yui'; var yuicombopath = ''; var remoteyui = false; } else // Load Rest of YUI remotely (where possible) { var yuipath = 'http://yui.yahooapis.com/2.9.0/build'; var yuicombopath = 'http://yui.yahooapis.com/combo'; var remoteyui = true; if (!yuicombopath) { document.write('
Yeah it is.
Cavs fans are the big loser.
I feel horrible for Byron Scott...he along w/ the city of Cleveland is the biggest loser. Kinda reminds me of Elton Brand bouncing from the Clippers when Baron Davis arrived.
Larry Bird and Ryan Grigson- wasting the talents of Paul George and Andrew Luck
I feel pretty bad for Cleveland fans but they still have some talent. The Nets have to be stinging as well. More teams that may be trading partners?
Tom Izzo.
I think the Cavs will win more games than us next season.
Heck, if they found a way to lose more games in Lebron's first couple years in the league, they would've probably been able to get better help around him (along with not foolishly losing Boozer for nothing).
Biggest loser in all this? I'd have to say the small market teams of the NBA. That was a kick in the teeth, not only to Cleveland, but to the small market teams in general.
Cleveland, no doubt. Followed by the Nets and like Quickrelease notes above the small market teams in the NBA.The way Lebron did this was really shameless.
2012 PD ABA Fantasy Keeper League Champion, sports.ws
2011 PD ABA Fantasy Keeper League Champion, sports.ws
2006 PD ABA Fantasy League runner up, sports.ws
For me personally, the Celtics, Lakers, and Pistons come out way big winners. I now have a team I will dislike more than them.
Personally, I don't see Miami remaining in such good shape in the future. They might get back to back titles, which is hell of an accomplishment, but IMHO it will crumble apart. They won't be holding hands, singing together for long.
Chicago will be in good position, when that time comes to step right in and be the big dog on the block.
Orlando hasn't figured out a game plan, they just seem to be arranging chairs just for the sake of saying they're doing something. And Boston is just getting old, and obviously, putting their eggs back in the Big 3 w/ Rondo basket.
Here's a thought... would the Cav's consider trying to aquire Gilbert Arenas now for peanuts since I'm sure he is readily available for short contracts? He's no Lebron for sure, but he could fill that #1 scorer void and they could probably be a pretty decent team with the complimentary pieces they already have in place.
If they want to win now, thats the only forseeable option I see. It would at least make them a mid/low-level playoff team I think, certainly no contender.
"As a bearded man, i was very disappointed in Love. I am gathering other bearded men to discuss the status of Kevin Love's beard. I am motioning that it must be shaved."
- ilive4sports
Oh, another Winner - Tiger Woods, guess whose not sports public enemy #1 anymore
1a.) Cleveland need to clean house, tank, like they did for Lebron and start from scratch; they won't do it, so I guess this is #1. You can't lose a 2 time Mvp and not be #1 on this list.
1b.) New York, they have given up FUTURE AND PAST #1s to position for Lebron and got Stoudamire, traded David Lee who well is probably as good as Stoudamire w/o Steve Nash. I'd guess by Feb 2011, Amare will ask to be traded. NY will want to. No one will take his salary.
None of these 3 really,
NJ still has a nice big man in Lopez, Favors has a bright future down the line, Devin Harris is still good PG, I really like TWILL and Damion James. I mean I thought this was the 2nd best place for Lebron as far as fit.
LA has Blake Griffin and a stud starting 5, imo. They should make the playoffs by accident. Well except for the curse of injuries and mismanagement, historically.
Chicago with a 3rd year D Rose, Noah - one of the best defensive/rebounding bigs, and now Boozer with Deng on the wing. I mean aren't they 4th best in the East now?
In my opinion, nobody is a bigger loser than LeBron himself.
I agree but as all us Pacer fans know being a .500 team is worse than being totally horrible in the long run. I think if Cleveland is smart they just clean house and start anew... right now.
Big losers ... New York and Cleveland
Big winners... Miami and Chicago... Watch out for the Bulls....
Another team we are forgeting about and should be in second place is Toronto, Bosh left them and they did not get anything in return either.
I honestly don't have a problem with LeBron wanting to team up with Wade and Bosh in Miami. It's just the way he went about it. He's such a celebrity now that he's lost all touch with reality and the way things are. If he actually used that brain of his, he'd have realized that Cleveland is a city on it's way to becoming like Detroit. To make a spectacle of his announcement to ditch the Cavs to play with friends is a total joke and a mockery of the NBA.
ESPN has seriously lost it's way too, and just plain sold out. It's all about big market teams that get the biggest ratings and that's it. I honestly can't stand ESPN any longer.
I feel terrible for the city of Cleveland and its fans as they are the biggest losers in more ways than just losing LeBron. It's right up there with the Pacer's brawl. Both the Pacers at that time were in contention for a championship as were the Cavs and now it's only a bitter memory.
It's good to want to play with friends, but sometimes you just have to do what's right. The right thing would have been to work your *** off to bring a championship to Cleveland, Ohio and your hometown. However, if you are going to leave the Cavs, I think it would have been smarter to meet with the owner of the Cavs and have a local press conference expressing thanks for the city and fans. I think something more intimate and candid would have lessened the sting.
Instead, LeBron is now just a joke.
First time in a long time, I've been happy with the team that was constructed, and now they struggle. I blame the coach.
Well, I don't know if this fits anymore, after the trades, but I thought it was funny. (From the Simmons article)
City: Cleveland
Name: Jeff
I've figured out the moral of the story: Stay in school.
Wade: 3 years at Marquette
Bosh: 1 year at Georgia Tech
The kid from Akron: no college
The most educated guy convinced his dumber friends to come play on his team for less money.
Actually the fact that he couldn't negotiate until July 1st and then sign until July 8th caused some of this, along with ESPN. He could have said a month ago that he was planning on going to Miami. Other teams could have concentrated on making themselves better overall than waiting on the royal penis interview. I do believe in doing whats best for yourself. The spectacle created by the media was not entirely LeBrons fault but he certainly didn't do anything to subside it.
"He wanted to get to that money time. Time when the hardware was on the table. That's when Roger was going to show up. So all we needed to do was stay close"
Darnell Hillman (Speaking of former teammate Roger Brown)


text:
SWINDON'S GP star Troy Batchelor is looking for support to help him compete in the series.
The Australian produced by far and away his best World Championship display in Copenhagen last time out, scorching to 20 points, which included six straight race wins, before he narrowly lost out to Niels-Kristian Iversen in the final.
However, having been a late call-up to the series in the winter as a replacement for legendary Pole Tomasz Gollob, Batchelor didn't have the time necessary to recruit an army of sponsors to help fund the considerable cost of competing at the highest level of the sport.
With Grand Prix prize money not always covering the costs of competing, life at the top can be hard, but Batchelor is hoping some help from local businesses might make things slightly easier.
"It's hard because I got the call at the last minute and I only had a couple of weeks to try and sort things before I had to go to New Zealand for the first round of the series, so sponsors were the last thing on my mind at that point," he said.
"I picked up a few little ones here and there and they've really helped but I haven't got a major team sponsor like a lot of the other guys do.
"It's been tough because some of the prize money at the GPs isn't very good, especially when you don't do so well, so all the help I could get would be amazing. There's non-stop opportunities really, with kevlars, bike covers, hats, internet, pit boards and all the mechanics too. They get seen on TV really clearly during the Grand Prix so it's good to show off your business.
"There's a lot we can do, so it would be great to get some help on board."
Batchelor's display at PARKEN sent him rocketing up the Grand Prix standings to 11th, putting him back in touch with the top eight, which provides his best route back into the series for the 2015 season.
"We'll see if we can do that (performance in Denmark) again but one of my goals this year was to get on a podium and then the second was to stay in the championship for next year.
"Last week in Denmark really helped with that, so I keep re-evaluating my goals every week to make sure I'm always pushing myself.
"I'm really looking forward to Cardiff and looking for a good result there, which would help push me even more."
Anyone interested in sponsoring Batchelor can contact him via @batchattack1 on Twitter or emailing email@example.com and the messages will be passed on.


text:
Announcing New Property Records Website
"Under Construction"
Click on link to the right
Welcome to Ford County Government
On February 17, 1859 Ford County became the 102nd and last county to be established in the State of Illinois. The county's first permanent courthouse was completed on February 13, 1862. The existing courthouse was built in 1906. In order to settle a dispute between Paxton and Gibson City as to where the new courthouse should be located, the old courthouse was "remodeled". When the old building was torn down, one wall in the basement was left standing. The new building was built upon and around it, thus ending the argument.
Located in East Central Illinois the county offices can be found at the following locations:
Courthouse, 200 W. State, Paxton
Hours: 8:30 AM - 4:30 PM
Sheriff & Jail, 235 N. American, Paxton
Hours: 8:00 AM - 5:00 PM
Highway Dept., 305 N St Rte 54, Roberts
Hours: 7:00 AM - 3:30 PM
This site is dedicated to providing information on county government to the citizens and property owners of Ford County. Our goal is to improve citizen access to county services. We encourage you to use this website to access information about your property and your government. We strive to provide accurate information.


text:
This game was classified by the community with the following category scores - Violence=0/3, Sex=0/3, Mature Content=0/3. Color Ball is a fast and fun casual game for your XBOX 360 game console. Play over 100 levels of fun. Shooting the colored balls into the goals to score points. Combine primary colored balls to create a secondary colored ball. Separate secondary colored balls into two primary colored balls.
Buy Xbox content on Xbox.com. Your Xbox 360 console will automatically download the content next time you turn it on and connect to Xbox Live.Learn More


text:
We don't just love Taco Joint for its great food. We love guys who can make us laugh. They did just that with today's special. As it turned out, today's special was actually spicy fried chicken tacos.
And if you have no idea what they mean by this, then by all means, catch up.


text:
An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients (POISE)
This study has been completed.
Janssen Inc.
Information provided by (Responsible Party):
Janssen Inc.
ClinicalTrials.gov Identifier:
First received: June 6, 2012
Last updated: May 20, 2014
Last verified: May 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Detailed Description:
The purpose of this study is to evaluate tolerability of darunavir (PREZISTA) or etravirine (INTELENCE) in patients infected with human immunodeficiency virus type 1 (HIV-1) who are naïve to these medications and in patients who have experienced tolerability issues on their current or prior combination antiretroviral therapy (cART). The tolerability is evaluated by switching the patients from their previous or current combination antiretroviral therapy (cART) to either darunavir or etravirine.
|Human Immunodeficiency Virus (HIV)
|Drug: darunavir (PREZISTA) Drug: etravirine (INTELENCE) Drug: ritonavir Drug: Other antiretroviral medications
|Phase 4
|Study Type:
|Study Design:
|Observational Model: Cohort
Time Perspective: Prospective
|Official Title:
|PREZISTA or INTELENCE Switch Evaluation in Virologically Suppressed Patients Naïve to Darunavir or Etravirine and Who Are Intolerant of Their Current or Prior Combination Antiretroviral Therapy Regimen: A Phase IV, Open-label, Multicentre Observational Trial
Resource links provided by NLM:
MedlinePlus related topics: HIV/AIDS
Drug Information available for: Darunavir Etravirine Darunavir ethanolateU.S. FDA Resources
Further study details as provided by Janssen Inc.:
Primary Outcome Measures:
- Change from Baseline in the patient's total score of the HIV Symptom Distress Module (HIV-SDM) [ Time Frame: Baseline (Day 1), Week 4, 12 and 24 ]HIV-SDM is a questionnaire consisting of 20 questions related to all the symptoms which the patient might have had during the past four weeks. For each question patient has to select appropriate answer related to the symptoms: "0 = I do not have this symptom; 1 = I have this symptom and it doesn't bother me; 2 = it bothers me a little; 3 = it bothers me; 4 = it bothers me a lot". Total score of HIV-SDM is then calculated for all the 20 items.
Secondary Outcome Measures:
- Number of participants with Maintenance/achievement of virologic suppression at Week 24 [ Time Frame: Baseline and Week 24 ]Virologic suppression is decrease in the number of virus in blood. Number of participants with virologic suppression (who achieved virologic suppression) as well as the Number of participants who maintained virologic suppression will be summarized.
- Number of participants with disappearance by Week 4 of at least one bothersome symptom identified at baseline by patient on HIV-SDM [ Time Frame: Baseline and Week 4 ]The bothersome symptoms (defined as those reported as 'It bothers me a lot' or 'It bothers me') at baseline will be identified for each patient. The number of participants who report the disappearance of at least one of the bothersome symptoms (eg, reported as 'It bothers me a little', 'It does not bothers me', 'I do not have the symptom') by Week 4 will be summarized.
- Number of participants with maintenance of disappearance by Week 12 and Week 24 of at least one bothersome symptom identified at baseline by patient on HIV-SDM [ Time Frame: Baseline, Week 12 and Week 24 ]The number of participants who report the maintenance of the disappearance of at least one of the bothersome symptoms (eg, reported as It bothers me a little, 'It does not bothers me', 'I do not have the symptom') at Week 12 and Week 24 will be summarized.
- Number of participants with Maintenance/increase in CD4 cell count. [ Time Frame: Baseline and Week 24 ]CD4 cells (a type of white blood cells) are circulating in blood and gives an idea of how strong the HIV positive person's immune system really is. The values of CD4 cell counts will be summarized using mean, standard deviations, minimum and maximum at baseline and Week 24. In addition, the number of participants with maintenance or increase in CD4 cell counts will be summarized.
- Comparison of change in HIV-SDM scores between those participants who were on or off ARTs at baseline [ Time Frame: Baseline, Week 4, Week 12 and Week 24 ]On and off ARTs is patients taking HIV medications and patients not taking HIV medications. The HIV-SDM change from baseline scores will be summarized using basic statistics (mean, standard deviations, minimum and maximum) by whether the patient is on or off ART at baseline.
|Study Start Date:
|October 2011
|Study Completion Date:
|April 2013
|Primary Completion Date:
|April 2013 (Final data collection date for primary outcome measure)
|Assigned Interventions
darunavir (PREZISTA)
PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)
Drug: darunavir (PREZISTA)
Form = tablet, route = oral, Units = mg, number = 800 administered once dailyDrug: ritonavir
Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
etravirine (INTELENCE)
INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)
Drug: etravirine (INTELENCE)
Form = tablet, route = oral, Unit = mg, number = 200, administered twice dailyDrug: Other antiretroviral medications
Given as per Canadian Product Monograph
Detailed Description:
This is an open label (all people know the identity of the intervention.), multicenter (study conducted at multiple sites), observational study (individuals are observed for certain outcomes) of darunavir and etravirine in patients infected with HIV-1 who are naïve to these medications and who have experienced tolerability issues on their current or prior combination antiretroviral therapy (medicines used for treatment of HIV). PREZISTA is indicated for naïve HIV patients (someone who has never used HIV drugs) and treatment-experienced HIV patients and INTELENCE is indicated for treatment-experienced patients who have failed prior therapy and have HIV-1 strains resistant to multiple antiretroviral agents (HIV-1 strains are able to survive the exposure of the multiple antiretroviral agents), including Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs). In this study patients will receive either darunavir (PREZISTA) or etravirine (INTELENCE) and physician selected optimized background agents (other antiretroviral medicines), as permitted by the local formulary and supported by the current Canadian Product Monograph. 90 patients will participate in this study (75 Patients planned for the darunavir group and 15 patients planned for the etravirine group). The total duration of the study will be 24 weeks. Safety and tolerability will be evaluated at screening (14 days prior to Day 1), baseline (patient's medical status before any treatment or research is done) at Day 1, Week 4, Week 12 and Week 24. Tolerability will be evaluated using HIV Symptom Distress Module (HIV-SDM) also referred to as the HIV Symptom Index (HSI) which is a self-completed questionnaire to evaluate symptoms and measure the presence and bothersomeness of side effects commonly seen with HIV and antiretroviral treatment over the last 4 weeks (20 questions about all symptoms which the patient might have had during the past four weeks). Higher scores indicate the presence of more symptoms and/or a greater degree of distress related to the 20 symptoms. In HIV-SDM data is collected to see the benefit of switching to either darunavir or etravirine.
|Ages Eligible for Study:
|18 Years to 75 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
|Sampling Method:
|Non-Probability Sample
Study Population
Patients infected with human immunodeficiency virus type 1 who have experienced tolerability issues on their current or prior ccombination antiretroviral therapy regimen and for whom a regimen including darunavir and/or etravirine is clinically indicated.
Inclusion Criteria:
- Have a documented HIV-1 infection
- Have 1 or more significant symptoms with at least grade 2 toxicity on the Division of AIDS Toxicity "DAIDS grading scale" on current or prior combination antiretroviral therapy (cART) regimen (current or prior cART including regimens consisting of 2 Nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent with the exception of darunavir or etravirine)
- Have stable response to current cART ie, have an HIV-plasma viral load [number of virus in blood] at screening <400 copies/mL (undetectable) or last plasma viral load on prior regimen within the previous 6 months <400 copies/mL)
- Must not have resistance to Primary HIV protease inhibitor medicines
Exclusion Criteria:
- Has been Infected with HIV-2 - Has received previous treatment with darunavir or etravirine or non-HAART (Highly Active Antiretroviral Therapy) regimen
- Has had prior virologic failure to 2 or more regimens or single virologic failure on prior cART
- Has a documented resistance to darunavir and etravirine
- Is currently using any drug contraindicated in the current Canadian Product Monograph for darunavir or etravirine
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01615601
Please refer to this study by its ClinicalTrials.gov identifier: NCT01615601
|Vancouver, Canada
Sponsors and Collaborators
Janssen Inc.
|Study Director:
|Janssen Inc. Clinical Trial
|Janssen Inc.
More Information
Keywords provided by Janssen Inc.:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 21, 2017
|Responsible Party:
|Janssen Inc.
|ClinicalTrials.gov Identifier:
|NCT01615601 History of Changes
|Other Study ID Numbers:
TMC114HIV4068 ( Other Identifier: Janssen Inc. )
|Study First Received:
|June 6, 2012
|Last Updated:
|May 20, 2014
Keywords provided by Janssen Inc.:
Human Immunodeficiency Virus
HIV type 1
HIV symptom Distress Module
Antiretroviral therapy
HIV Symptom Index (HSI),
Additional relevant MeSH terms:
Immunologic Deficiency Syndromes
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
ClinicalTrials.gov processed this record on September 21, 2017


text:
USAID Associate Administrator Mark Feierstein visits Yemen
For Immediate Release
SANA'A, YEMEN – This week the United States Agency for International Development's (USAID) Associate Administrator (AA), Mark Feierstein traveled to Yemen to announce a $21.5 million assistance package and reaffirm the United States' continuing support and assistance to the country during its historic political transition. Accompanying AA Feierstein, Deputy Assistant Administrator for the Middle East Bureau Alina Romanowski returned to Yemen for her second time this year, reinforcing the importance of USAID's engagement in Yemen and its commitment to a successful transition.
The $21.5 million in assistance will be used to expand the success of ongoing USAID projects in education, health, and agriculture. The additional funding brings USAID's total assistance to Yemen in 2013 to over $176 million, the largest amount USAID has ever provided to Yemen in one year. Of the funds, $4.8 million will amplify the successful Early Grade Reading program accredited by the Ministry of Education and further school rehabilitation efforts; $11.7 million will expand health programs; and almost $5 million will be used for agricultural activities.
In a meeting with Yemeni President Hadi, Assistant Administrator Feierstein reaffirmed the need to move forward on critical economic and political reforms. Mr. Feierstein also noted the importance of the long-standing relationship between the United States and Yemen saying, "these funds are helping Yemen build a brighter future and we are proud to be a part of its success."
The visit of the USAID delegation to Yemen also included meetings with the National Dialogue Secretariat, Yemeni entrepreneurs, and local women leaders as well as site visits to USAID-supported projects, including a recently rehabilitated hospital and the new data center for the Supreme Commission for Elections and Referendums.
Last updated: March 17, 2014


text:
Topic: clincial trial/chemo options for my dad?
This post is copied (with some modifications) from my first post yesterday under Introductions, but since I haven't received any comments, I thought maybe it was more appropriate under this category. Sorry if I'm breaking protocol by posting the same info twice, I'm new to these message boards and I'm really trying to find out as much as possible to help my dad decide what to do.
My dad, who's 75, was diagnosed with an extrahepatic bile duct tumor in March and had the Whipple procedure at the Mayo in Jacksonville in April. During surgery they found some spots (largest was 1 cm) in his liver which on initial biopsy were reported as benign, but the final pathology report said that 2 of them were indeed cancer that had metastasized from the bile duct. The primary tumor was about 1.5 cm and had attached to the portal vein. The surgeon was able to resect from the portal vein and also removed the 4 spots he saw on the liver. Due to the involvement of the portal vein and the metastases in the liver, his cancer was categorized as Stage IV. His lymph nodes and his pancreas were clean, so it's just the liver at this point.
The oncologist at Mayo is recommending chemo. He has offered my dad to participate in a clinical trial of Avastin and Tarceva or he could go a standard protocol of chemo with Gemzar. I am a bit worried by the potentially serious side effects of the Avastin and was wondering if anyone has had any experience with this trial or either of these drugs.
My dad feels so good right now and it's unclear to me as to whether this treatment will prolong his life significantly and if it's worth the potential serious risks and side effects. We're also having trouble deciding what to do next because we don't really know if he has any visible tumors in the liver right now, since the surgeon said he removed the spots he did see during the surgery.
If anyone has experience with these drugs and their sides effects I would really love to hear from you. Also any thoughts in general on whether to go with the chemo at all at this point would be much appreciated.
Thanks so much,


text:
Acquired Engineering360
Since their establishment in the United States in 1957, Yokogawa Corporation of America has become a leading manufacturer and supplier of test, measurement, field instrumentation, process control and information products for North America.
Headquartered just south of Atlanta, Georgia, Yokogawa has sales offices across the United States. Their commitment to their customers is Yokogawa's number one priority, and they back it up with a network of representatives and distributors that reflect this commitment.
Their parent company, Yokogawa Electric Corporation, is dedicated to developing the most advanced control and instrumentation products and systems in the world. Today, Yokogawa has a firm hold on its position as a leading manufacturer in the fields of measurement, control, and information. As a major global player, the company anticipates the needs of the times, continually tackling new challenges and exploring new markets in order to provide the best solutions in the world.
Yokogawa's commitment to innovation is reflected in their extraordinary investments in R&D, which ensure development of the most advanced products and services. Yokogawa has consistently made above-average investments in research and development. In fact, over the past decade, they have set an industry standard by committing a full nine percent of sales revenue each year to R&D. As a result, they have secured more than 4,500 patents and registrations, representing a number of important innovations, including the world's first distributed control system and the first digital sensors for flow and pressure measurement.


text:
Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow's leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic's many resources and see jobs available for medical professionals. Get updates.
Give to Mayo ClinicHelp set a new world standard in care for people everywhere. Give now.
Subscribe to Housecall
Our general interest e-newsletter keeps you up to date on a wide variety of health topics.
Acidic polysaccharides, American angelica, angelol, angelica, Angelica acutiloba, Angelica archangelica, Angelica atropurpurea, Angelica dahurica, Angelica edulis, Angelica gigas, Angelica keiskei, Angelica koreana, Angelicapolymorpha var. sinensis Oliv., Angelica pubescens, Angelica radix, Angelica root, Angelica silvestris, Angelica sinensis (Oliv.) Diels, angelicide, angelicin, angelicone, angelique, anodynes, Apiaceae (family), Archangelica officinalis Moench or Hoffm., bergapten, beta-sitosterol, Chinese angelica, Chinese danggui, coumarins, dang gui, dang gui ku shen wan, dang quai, dāngguī (pinyin), Danggui-Nian-Tong-Tang (DGNTT), danggwi (Korean), dong kwai, dong qua, dong qui, dry-kuei, empress of the herbs, Engelwurzel (German), eumenol, European angelica, female ginseng, ferulic acid, flavescent sophora root, flavonoids, furanocoumarins, garden angelica, Heiligenwurzel (German), Japanese angelica, kinesisk kvan (Danish), kinesisk kvanurt (Danish), lactones, Ligusticum glaucescens Franch., Ligusticum officinale Koch, ligustilides, Moon CycleTM tea, phytoestrogen, psoralens, qingui, radix Angelica sinensis, root of the Holy Ghost, sodium ferulate (SF), sovereign herb for women, tan kue bai zhi, tang kuei, tang kuei root, tang kwei, tang quai, tanggui (Korean), tanggwi (Korean), toki (Japanese), wild angelica, wild chin quai, Women's EnergyTM tea, women's ginseng, yuan nan wild dong quai, yungui.
Selected combination products: Angelica-alunite solution, angelica-paeonia powder, Bloussant( breast enhancement tablets, Bust Plus(, danggui huoxue tang (blood stimulant decoction of dong quai), danggui buxue tang (dong quai hematinic decoction), hormonal and immune system tonic, Four Things Soup (dong quai, Rehmannia glutinosa, Ligusticum wallichii, and Paeonia lactiflora), koo sar pills (containing 11 ingredients, including dong quai), Phyto-Female Complex (SupHerb®, Netanya, Israel; ingredients: standardized extracts of black cohosh, dong quai, milk thistle, red clover, American ginseng, and chaste-tree berry), shou wu chih, dong quai four, shenyan huayu tang (decoction for nephritis and stasis), Sini decoction, Siwu tang, shimotus to, tokishakuyakusan, xiao yao powder, xiao yao wan ("free and easy wanderer," Bupleurum, and dong quai), yishen tang (kidney tonic decoction).
Note: Angelica dahurica is commonly known as Chinese angelica; however, it is not included in this bottom line.
Portions of this document last updated: Nov. 01, 2013
This evidence-based monograph was prepared by The Natural Standard Research Collaboration
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.
Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below.
We comply with the HONcode standard for trustworthy health information: verify here.


text:
Help for Homeowners
NCRC offers free foreclosure prevention and first time homebuyer counseling services. Current or prospective homeowners receive assistance from our Housing Counseling Network, composed of Department of Housing and Urban Development certified housing counselors nationwide. Our counselors are loan workout experts, especially trained to negotiate equitable solutions on behalf of homeowners.
Facing foreclosure or think you might be the victim of a scam or predatory loan product? Contact our housing counselors today at 1-800-475-NCRC.


text:
Screening for Thoracic Aortic Aneurysm Among a Cohort of Patients With a Degenerative Abdominal Aortic Aneurysm
This study is currently recruiting participants.
Verified September 2016 by Assistance Publique Hopitaux De Marseille
Assistance Publique Hopitaux De Marseille
Information provided by (Responsible Party):
Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:
First received: April 10, 2012
Last updated: October 17, 2016
Last verified: September 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Detailed Description:
Many publications deal with the natural history of aortic aneurysms in literature. Except for connective tissue disorders as Marfan or Loeys-Dietz syndrome, aortic aneurysms are a complex multifactorial disease with genetic and environmental risk factors. Susceptibility loci identified in thoracic aortic aneurysms (TAA) and abdominal aortic aneurysms (AAA) do not overlap, suggesting that different genetic risk factors contribute to these two forms of aneuryms. With a higher prevalence correlated to ageing (5%), AAA is usually presented as the degenerative form of the disease. However, a recent epidemiologic study by Olsson et al. has revealed an increasing incidence of thoracic aortic disease among older individuals (70+/-12 years) with 60% of aneurysmal rupture or dissection at diagnosis, and a 1.7 :1 male-to-female ratio compared to 6:1 in AAA. From this current knowledge arises the concept of diffuse or plurisegmental degenerative aneurysmal aortic disease, poorly explored so far. As regards to the prevention policy, there is a consensus statement in which ultrasonography screening for AAA is recommended for all individuals aged > 60 years (particularly in men who have ever smoked) and for those aged > 50 years with family history of AAA. Nevertheless, screening for a concomittant thoracic location of the disease (except thoracoabdominal aneurysm) is not yet required, whereas it could change the prognosis of the patients and influence their management.
|Abdominal Aortic Aneurysms
|Other: blood samples
|Study Type:
|Study Design:
|Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
|Official Title:
|Screening for Thoracic Aortic Aneurysm Among a Cohort of Patients With a Degenerative Abdominal Aortic Aneurysm : Prevalence, Description of the Different Thoracic Aortic Phenotypes by Aortic Volumetric Numerized Imaging and Their Relationship With Epidemiologic, Clinical, Biological and Genetic Factors
Resource links provided by NLM:
MedlinePlus related topics: Aneurysms Aortic AneurysmU.S. FDA Resources
Further study details as provided by Assistance Publique Hopitaux De Marseille:
Primary Outcome Measures:
- BLOOD SAMPLES [ Time Frame: 3 YEARS ]to determine the prevalence thoracic aortic aneurysms (TAA) and abdominal aortic aneurysms (AAA)
Secondary Outcome Measures:
- ANGIOSCAN [ Time Frame: 3 YEARS ]the validation of volumetric criteria to quantify the aortic remodeling in TAA or untreated AAA
- CARDIAC STATEMENT [ Time Frame: 3 YEARS ]cardiac echography
|Estimated Enrollment:
|Study Start Date:
|June 2012
|Estimated Study Completion Date:
|March 2017
|Estimated Primary Completion Date:
|February 2017 (Final data collection date for primary outcome measure)
|Assigned Interventions
|abdominal aortic aneurysms
|Other: blood samples
Detailed Description:
Through the constitution of a multicentric prospective cohort of patients with infra-renal AAA (n=450), the investigators aimed to determine the prevalence of a concomitant TAA, and the epidemiologic, clinical, biological and genetic factors related to this aortic phenotype. Therefore, the investigators postulate for a prevalence of the AAA-TAA association inferior or equal to 15%. By the use of an innovating software (AMIRA) to analyse scans, the investigators will perform reproductive measurements of segmental diameters from a segmental aortic volumetric numerized imaging, and describe the different thoracic aortic phenotypes associated with AAA, including the form (TAA, penetrating ulcer, dolichoaorta …) and the location of the disease.
|Ages Eligible for Study:
|18 Years and older (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Major subject at the time of the inclusion
- Subject sent in hospitalization or in consultation of surgery vascular for coverage of the first one anévrysme of the sub-renal abdominal aorta degenerative, without anomaly associated by the coeliac aorta, and by the upper diameter in 40mm (according to the criteria of measure recommended for the analysis in echography doppler or in angioscanner).
- subject not presenting contraindication to the realization of the diagnostic examination by aortic angioscanner
- Subject having signed a consent.
Exclusion Criteria:
Subject under age 18
- pregnant Woman
- Subject received in the phase aigue of a break or a fissuring of an AAA under renal
- Subject already operated for a thoracic or abdominal aortic anévrysme
- Subject presenting at least one of the following pathologies:
- heart disorder valvulaire aortic: aortic incapacity of rank superior to 2, tight aortic stenosis, prosthesis valvulaire aortic
- context of bicuspidie station wagon diagnosed on at least 2 parents of the first degree
- of a not degenerative aortopathie anévrysmale bound(connected) in bicuspidie aortic, or: A dissection of type(chap) A or of type(chap) B
- Of a degenerative aortopathie of type anévrysme thoracoabdominal (in particular, affected by the coeliac aorta, defined by the segment enter the diaphragmatique crossing and the renal arteries)
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01599533
Please refer to this study by its ClinicalTrials.gov identifier: NCT01599533
|Contact: philippe PIQUET
|Assistance Publique Hopitaux de Marseille
|Marseille, France, 13354
|Contact: philippe PIQUET firstname.lastname@example.com
|Principal Investigator: philippe piquet
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
|Study Director:
|Assistance Publique hôpitaux de Marseille
More Information
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 25, 2017
|Responsible Party:
|Assistance Publique Hopitaux De Marseille
|ClinicalTrials.gov Identifier:
|NCT01599533 History of Changes
|Other Study ID Numbers:
2012-01 ( Other Identifier: AP HM )
|Study First Received:
|April 10, 2012
|Last Updated:
|October 17, 2016
Additional relevant MeSH terms:
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Aortic Aneurysm, Thoracic
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases
ClinicalTrials.gov processed this record on September 25, 2017


text:
My colleague, former Microsoftie and Sage-ite Steve Cover, posted a link to a thought provoking article on Intercom.io. Titled "The End Of Apps As We Know Them", it claims that designers and developers need to focus more on designing apps as systems that interact with other applications and OS'es, and less as stand-alone destinations. It's basically an argument for focusing on workflow, which as a UX designer and researcher makes me very happy.
Some of the implications of their claims are almost mind-blowing. Here's just one. From the article:
"Responsive design is a nice thing, but we're heading way beyond that. We're talking about designing content that may appear on an incomprehensible number of devices and in an incomprehensible number of situations. This will need new design principles, new ways of thinking about researching context."
There's lots more to chew on in the article, and some great comments too. Check it out.


text:
set_logger() method is not actually setting a logger at all, which is confusing. It's setting a callback that returns a logger, so maybe it should be
set_logger_factory() or something like that. This is particularly problematic since there's a
get_logger() method, which doesn't return the thing passed to
You're right,
set_logger()should be renamed, though I'm not sure I can bear to use "factory".
The name you are looking for is


text:
What Kim Sears Wore to Wimbledon 2013
It's Official: Kim Sears Has Grand-Slam Style
It's Official: Kim Sears Has Grand-Slam Style
If there was an actual decoration for the First Lady of Wimbledon, the title would have to go to Kim Sears. Longtime girlfriend to Andy Murray, the men's singles champ who claimed the honor for Britain after a 77-year drought, Kim played the part of supportive (and well-dressed) girlfriend to perfection.
Haven't heard of Kim yet? Before clicking through her sophisticated courtside outfits, know this: that chestnut mane has led the British to pit her against Kate Middleton for the best hair superlative. And in our book, any time you're being compared to the duchess, you're winning.
0previous images
-23more images


text:
The United States junior national team will enjoy a perfect July 4 holiday.
The Americans are the only unbeaten team through two rounds at the FIBA U19 World Championship following their 71-62 victory Wednesday over previously undefeated Serbia. They advance to the quarterfinal round Friday against Canada, which also features some U.S. collegians and top college prospects.
Along with Serbia, Spain had entered the final day of second-round play with a perfect mark, but the Spaniards fell 61-59 to Lithuania.
As expected, Serbia gave the U.S. its most difficult test to date. Particularly with their own point guard in foul trouble, the Americans had trouble defending point guard Vasilje Micic, who scored 24 points as he went to the line for a dozen free throws and converted all but three. He also was 3-of-5 on 3-pointers, but Serbia as a team did not shoot well from deep.
The U.S. was wise to lean on high school center Jahlil Okafor of Chicago's Whitney Young, the No. 1 prospect in the 2014 recruiting class. He showed why he is such a coveted recruit by scoring 16 points on 7-of-11 shooting. The U.S. also got 11 points from versatile Arizona-bound forward Aaron Gordon and 15 from Duke guard Rasheed Sulaimon, who hit perhaps the biggest basket of the game.
The U.S. pressure defense pulled 12 steals from Serbia and scored 19 points off turnovers, but all this didn't completely buckle this opponent as so many others.
High school senior Justise Winslow of Houston St. John's was effective defensively as usual, picking up 2 steals, grabbing 6 rebounds and scoring 8 points. Power forward Montrezl Harrell of Louisville scored 9 points and grabbed 7 rebounds.
The U.S. decided to all but abandon the 3-point game, having struggled throughout the tournament to shoot successfully from long range. Though averaging 100 points through five games, the Americans had been making only 29.2 percent of their 3-point attempts.
Through three quarters against Serbia, only Gordon had tried one, and he missed. When Sulaimon finally hit the first 3 for the U.S., it was a big one, stretching a tight 56-52 lead to a more comfortable 59-52 advantage with a little more than 6 minutes remaining in the game.
The U.S. played nearly the entire way without their leader, point guard Marcus Smart, who picked up three fouls in the first half and a fourth early in the third quarter. Through three quarters, he had played less than eight of a possible 30 minutes.
As the U.S. was able to stretch its lead from three points at the close of the third period to 63-54 with 3:32 left, coach Billy Donovan kept Smart on the bench and allowed Washington-bound Nigel Williams-Goss to handle most of the playmaking duties. When Smart entered to try to help close the game, he lasted a little more than a minute before being disqualified.
Canada needed to win Wednesday to qualify for the quarters and blew out Argentina, 78-62, behind 21 points from Indianapolis high school senior big man Trey Lyles, 17 from Syracuse-bound guard Tyler Ennis and 16 from Florida State-bound guard Xavier Rathan-Mayes. The U.S.-Canada game and all elimination-round games will be available to be viewed over the Internet—for a fee—on FIBA TV.


text:
^ Good.
'); var yuipath = 'clientscript/yui'; var yuicombopath = ''; var remoteyui = false; } else // Load Rest of YUI remotely (where possible) { var yuipath = 'http://yui.yahooapis.com/2.9.0/build'; var yuicombopath = 'http://yui.yahooapis.com/combo'; var remoteyui = true; if (!yuicombopath) { document.write('
^ Good.
I just think it says a lot that we have so many quality coaches that are candidates for the Pacers. We've come a lot way since JOB.
How did I fail?This quote is hidden because you are ignoring this member. Show Quote
I was first a T-Wolves fan as KG was my fav player when I started watching NBA basketball, and I stopped being a Wolves fan when KG was on his way out of there, but when Casey coached those Wolves, I thought he was a good coach, but the problem was he was left with a somewhat "declining" KG and absolutely nothing else to work with...I'd like to see what he could do with our roster, but I think Vogel should probably just stay with us.


text:
UW–Madison engineering alumni receive top college honor
On Friday, Oct. 14, the University of Wisconsin–Madison College of Engineering will recognize 10 alumni who have made key contributions to their profession and to society.
During the 64th annual Engineers' Day banquet, nine of these high-level engineers will receive the college Distinguished Achievement Award and one recent alumna will receive the Early-Career Achievement Award.
Distinguished Achievement Award recipients:
- Vincent Sik-Hung Chan, San Diego: For more than a decade, Chan has led the General Atomics theory and computational science division of the energy and electromagnetic systems group. He has contributed to a broad spectrum of plasma physics research and spearheaded the advanced tokamak concept for economical fusion energy. He is a champion for using high-performance computing in magnetic fusion research and has produced more than 100 broadly cited journal articles. Chan is a fellow of the American Physical Society and has participated on several fusion-related governmental and international committees. He earned bachelor's and master's degrees in electrical and computer engineering from UW–Madison in 1972 and 1973 and a Ph.D. in electrical engineering in 1975.
- Michael R. Duckett, Brookfield, Wis.: It's been a good year for baseball for Duckett, who is president of the Duckett Group Inc. of Brookfield and executive director for the Southeast Wisconsin Professional Baseball Park District. In his role, Duckett managed the planning, design and construction of Miller Park, the state-of-the-art Milwaukee Brewers baseball stadium. Now, he represents the public's interest in the ballpark and oversees its operation, capital repairs and improvements. Additionally, the Duckett Group has provided engineering and management services for numerous projects, including the Lambeau Field renovation and the Milwaukee Marquette Interchange reconstruction. Duckett earned his bachelor's degree and master's degrees in civil and environmental engineering from UW–Madison in 1974 and 1975 and is a licensed professional engineer and registered land surveyor.
- David U. Furrer, East Hartford, Conn.: As senior fellow and discipline lead for Pratt & Whitney, Furrer fills the company's highest technical position and has become a leading international authority on materials for aerospace applications, including turbine engines, airframes and rockets. Furrer's is a career that has come full circle: He began at the company as a materials engineer 25 years ago, then left to take positions at SSI Technologies, Ladish Co. Inc. and, until 2010, Rolls-Royce. In his role at Pratt & Whitney, Furrer leads all the materials discipline chiefs and materials fellows in developing technical strategy and improving all materials engineering work. He received his bachelor's and master's degrees in metallurgical engineering at UW–Madison in 1986 and 1988.
- J. Michael Jensen, Cincinnati: In a 34-year career with Procter and Gamble, Jensen coupled his love of technology with his passion for innovation. After holding several positions in research and development, Jensen retired in 2008 as global vice president of research and development for Procter and Gamble. Throughout his career, Jensen was especially adept at creating new or reinventing existing Procter and Gamble businesses whose products had major effects on the lives of consumers worldwide. Jensen also devoted energy as a recruiter to developing the company research and development organization itself and has been a champion — both inside and out of Procter and Gamble — for building a diverse, inclusive culture. He earned his bachelor's degree in chemical engineering from UW–Madison in 1973.
- Appu Kuttan, Alexandria, Va.: Pioneer of an influential management by systems concept that has been applied around the world, Kuttan is an expert in global systems and has advised government leaders on topics ranging from traffic safety to the economy. In 1989, he founded the National Educational Foundation, a nonprofit organization that bridges academic, digital and employment divides to make high-quality education accessible to everyone around the world, and in particular, in the United States and India. Kuttan also is author of several books, including "From Digital Divide to Digital Opportunity and Happy Executive — Nurturing Mind, Body and Soul." He earned his Ph.D. in industrial engineering from UW–Madison in 1968.
- Richard M. Lynch, Madison, Wis.: In a distinguished career that spans nearly 30 years with Madison construction firm J.H. Findorff and Son, Lynch has overseen projects ranging from the American Family Children's Hospital and Epic Systems campus to the Monona Terrace Community and Convention Center and the Overture Center for the Arts. Lynch started his career with the company in 1984 as a project manager and became an owner and vice president in 1992. He was named executive vice president in 1997 and president in 2002. Under Lynch's leadership, Findorff has remained at the forefront of cutting-edge construction processes, equipment and technology and is committed to using green building practices. Lynch earned his bachelor's degree in construction administration from UW–Madison in 1974.
- James R. Meister, Warrenville, Ill.: As Exelon vice president for operations support, Meister played a key role on the executive leadership team that transformed Commonwealth Edison from the worst nuclear operator in the United States into Exelon, a company that now is the best U.S. operator. With 17 nuclear reactors in Illinois, Pennsylvania and New Jersey, Exelon Nuclear is the largest operator of nuclear power plants in the United States and serves 5.4 million customers. Meister joined the company in 1994 and has served as station manager for several generating stations, as well as engineering vice president for Exelon Nuclear. He is a graduate of the Institute of Nuclear Power Operators senior nuclear plant manager course and of the Naval Postgraduate School Center for Homeland Defense and Security Executive Leadership Program. Meister earned his bachelor's degree in nuclear engineering from UW–Madison in 1978.
- Brian J. Rauch, Dubuque, Iowa: Vice president of engineering for the John Deere Dubuque Works Worldwide Construction and Forestry Division, Rauch leads 600 engineers in a global organization that develops construction and forestry equipment, such as backhoes, bulldozers, skidders and forestry harvesters. Among its recent innovations, the division has introduced an industry-first high-speed dozer and two hybrid-electric loaders. Rauch is known for his intense focus on Deere customers and enjoys developing innovations that increase Deere customers' profits and productivity and enhance the company reputation as an industry leader. He also is committed to diversifying the Deere workforce and played an integral role in assembling a multicultural, multinational team in the U.S. engineering center and building new talent in locations such as India and China. Rauch earned his master's and Ph.D. degrees in engineering mechanics from UW–Madison in 1990 and 1993.
- James D. Woodburn Jr., Deephaven, Minn.: President of Woodburn Health Consulting and chief medical officer and director of Applied Pathways, Woodburn transformed his experiences as a practicing physician into expertise in health care management. Rather than serving one patient at a time, he has developed systems that help millions nationwide.
He has advised high-tech companies and agencies, including the Nuclear Regulatory Commission, on occupational and environmental health issues and spearheaded the growth of MinuteClinic, a system of clinics in grocery and department stores that provides basic care in 30-minute appointments. Woodburn helped the system expand from just a handful of clinics to 250 clinics staffed by more than 2,000 nurse practitioners. He earned his bachelor's degree in electrical engineering from UW–Madison in 1977 and his master's degree in biomedical engineering in 1981.
Early Career Award recipient
- Jennifer A. Topinka, Houston: In only seven years, Topinka has established herself as a rising star at General Electric (GE). As the senior finance manager for GE Oil and Gas, Topinka is responsible for $200 million in research and development investment and engineering finances. Topinka's work stems from a passion for fuel efficiency and is listed as an inventor on four issued patents for new engine technologies, including a system to control fuel-injection events. At GE, she has championed environmental initiatives that focus on driving environmental responsibility: She co-founded two organizations, including we "c" green at the GE Global Research Center and EcoForum within the GE corporate audit staff. Topinka earned a bachelor's degree in mechanical engineering from UW–Madison in 2001.
Tags: College of Engineering


text:
Aunt pleads guilty to abusing girl found in container in 2011Posted: Updated:
The aunt of a 10-year-old Phoenix-area girl whose body was found in a plastic container in the torrid Arizona summer heat pleaded guilty to child abuse Friday.
Cynthia Stoltzmann, 45, who was also a legal guardian, pleaded guilty to two counts of child abuse and one count of attempted child abuse. She is set to be sentenced June 6.
Stoltzmann was accused of throwing Ame Deal into a cold swimming pool several months before the girl's death and forcing her head underwater.
Stoltzmann was also accused of once sitting on a footlocker while the girl was inside, being punished for stealing food at the family home.
The Maricopa County attorney will seek the death penalty for the two other people charged with murdering Ame.
Prosecutors say John "Bud" Allen and Samanthea Allen locked Ame inside the storage box in July 2011. Both of them have pleaded not guilty to the charges of first-degree murder, conspiracy to commit child abuse and multiple counts of child abuse.
Copyright 2013 CBS 5 (KPHO Broadcasting Corporation). All rights reserved. The Associated Press contributed to this report.


text:
WASHINGTON—There was a handful of times this season that Indiana didn't look like the No. 1 team in the country, or even like one of the sure-fire No. 1 seeds in the NCAA Tournament. Never did the Hoosiers look less like one than on Thursday night.
Syracuse, the fourth seed in the East Region, handled the top seed with amazing ease, in ways that weren't reflected in the 61-50 final score at Verizon Center. Syracuse dominated Indiana physically and had athletes that Indiana couldn't match up with. The Hoosiers' best players, almost to a man, withered away more as the game wore on.
MORE: Syracuse-Indiana stats | Interactive bracket | Sweet 16 photo gallery
Nobody could keep up with Syracuse's Michael Carter-Williams, who looked like the best player on the floor by far all night, finishing with 24 points and sparking the surge that put down Indiana's final attempt at a comeback. He nailed a huge 3-pointer with nine minutes left to stretch the Orange lead to 51-37 after it had shrunk to seven.
Thus, the team that spent so much time atop the polls in the regular season, and was considered a candidate for the top overall seed until the final weekend, went out with a whimper in the Sweet 16. Syracuse, fourth in the Big East standings and beaten soundly itself in its conference tournament final, moves on to an all-Big East showdown against Marquette in the Elite Eight on Saturday night.
That seems fair, because Indiana looked anything but elite. Except for Sporting News Player of the Year Victor Olapido, who did yeoman work at both ends trying to stay with the Orange, everybody else did a disappearing act. Cody Zeller, a Player of the Year candidate most of the season, was invisible most of the night, except when his dunk got blocked midway through the second half as Syracuse was beginning to pull away. He left with 30 seconds remaining with 10 points, on 3-for-11 shooting.
Jordan Hulls couldn't keep up at either end. Will Sheehey was off the mark from all over the floor, and Christian Watford only showed flashes of the versatility that had served the Hoosiers so well.
Carter-Williams and his teammates also turned the matchup zone into a weapon against the overmatched Indiana players, who needed 14 minutes of game time to crack double figures in total points. By that time they were down 22-9. They didn't help themselves by missing free throws literally from the very beginning (Oladipo, 23 seconds into the game); they finished 15-for-24 from the line.
Indiana was the second No. 1 seed to depart the tournament, after Gonzaga in the Round of 32. The other two, Louisville and Kansas, play their Sweet 16 games Friday.


text:
alan wrote:Throw that guy into laughing idiot jail. I hate it when people laugh out loud for no reason other than to call attention to themselves.
plwk wrote:A man from Long Island, New York, is facing up to 30 days in jail and a US$500 fine after a neighbour complained to police he was laughing too loudly, his lawyer said yesterday. More here
It is childish, bhikkhus, in the discipline of the noble ones to laugh excessively showing the teeth.
Therefore, bhikkhus, having given up singing, having given up dancing, it is suitable for you who delight in the Dhamma to smile moderately mindful smiles.
Ruṇṇa Sutta
I think the same thing is likely true about carping, grousing, and grumbling.alan wrote:"Bestial topics"...I'm sure you've read that one. (AN 10.70).
Also look at AN 10.93, which tells us the value of being fond of quietude.
Loud, pointless laughter, besides being a sign of spiritual immaturity, is also a social nuisance.
C, g, and g are best kept to one's self, as no more than a mumble or a bit of muttering. In the written form, however, they are as loud and out there as is anything else.alan wrote:Carping, grumbling and grousing are all well and fine, as long as they are not loud.
alan wrote:But wasn't this complaint about laughing out loud in public?
The problem seems to be the neighbor.Schiavelli said the neighbour regularly mocks his disability, and the best response to those taunts is laughter.
"He just ridicules me all the time and the only thing I can come up with is laughing," Schiavelli said in a telephone interview.
Users browsing this forum: No registered users and 53 guests


text:
Outside of the giant PS4 news this week, Mortal Kombat gets an AU release date, Synthesis opens in Singapore and PAX helps out indie developers.
- Prior to the confirmation that second-hand games would be playable on Playstation 4, EB Games Marketing Director Shane Stockwell was downtalking the weight of the rumours.
- EB Games Managing Director Stephen Wilson, meanwhile, was delighted with the Playstation 4 and expressed his eagerness for the new hardware.
- Following the recent classification of Mortal Kombat: Komplete Edition as R18+, Warner Bros has dated the Australian release of the title as 29th May.
- Localisation giant Synthesis has opened up a Singapore office to be the central hub of its Asian operations.
- PAX Australia has announced an Indie Showcase, where it will heavily promote the six best indie games made in Australia or New Zealand before and during the show.
- Sydney-based developer Nnooo has called for other independent developers to petition MP Andrew Stoner to renew the New South Wales Interactive Media Fund.


text:
DURSLEY Road Club had two riders in the top ten at the Chippenham 24-mile Hardriders Time Trial.
Battling the hills in galeforce conditions on a rough, wet pot-holed course, Simon Williams recorded an excellent 54 minutes, six seconds to take fourth place, followed closely by Mike Davis 57.07 in sixth place and strongly backed up by John Sirett one hour, four minutes.
It was an excellent day for Dursley in an event hosting 60 riders.


text:
Four FiguresRiddles are little poems or phrases that pose a question that needs answering. Riddles frequently rhyme, but this is not a requirement.
A row of four figures in value will be
Above seven thousand nine hundred and three;
But when they are halved, you'll find very fair
The sum will be nothing, in truth I declare.
Answer8888, which when divided horizontally along the middle line become zero.
What Next?
See another brain teaser just like this one...
Or, just get a random brain teaser
If you become a registered user you can vote on this riddle, keep track of
which ones you have seen, and even make your own.
Back to Top


text:
To Customer: When placing an order on dogwise.com, please
make sure
that you have cookies enabled in your web browser. To remove an item from your cart, enter a 0 in the quantity field and click update cart. Membership discounts will be calculated at checkout.
2016 - All rights reserved
Dogwise a Direct Book Service Inc. Company
403 S. Mission St., Wenatchee WA 98801, USA
Questions, Comments? Contact Us
Please read our Privacy Policy


text:
Here's Your No-Deal Fiscal Cliff Strategy
On the fiscal cliff, did you really expect anything to be done? Did you even want anything to be done? I've been convinced that no deal would happen, and I positioned myself accordingly. Now I'll tell you what will happen next and how to play it.
No deal happening is now a better outcome than a last-minute, superficial can-kick arrangement. Think about it: Wouldn't it be the greatest indictment of our incredibly dysfunctional government if Congress could manage to carve out some superficial deal in the last 18 hours of the year when it has been unable to do anything but jawbone for the past 18 months? Even an election seemed to settle nothing. What are we paying these guys for?...363 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.


text:
The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease
This study has been completed.
Newport Pharmaceuticals International
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: June 1989
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of Isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of the 28 days of treatment), measured by one or more of the following immunological parameters:
- Increase in natural killer (NK) cell activity.
- Increase in total T-cells (OKT-11).
- Increases in absolute number and percentage of T-helper cells (OKT-4).
|Lymphatic Disease HIV Infections
|Drug: Inosine pranobex
|Study Type:
|Study Design:
|Masking: Double
Primary Purpose: Treatment
|Official Title:
|A Multi-Center Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy
Resource links provided by NLM:
MedlinePlus related topics: HIV/AIDSU.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
|Ages Eligible for Study:
|18 Years to 50 Years (Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
- History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction and severe gastric ulcer.
- Lymphoid malignancy.
- Infectious mononucleosis caused by cytomegalovirus or Epstein-Barr virus.
- Heart disease (especially if receiving cardiac glycosides).
- Hemophilia.
Patients with the following are excluded:
- Kaposi's sarcoma or overt opportunistic infections as follows:
- Candida albicans, Pneumocystis carinii, Herpes simplex, Cryptococcus neoformans, Histoplasma capsulatum, Mycobacterium avium-intracellulare, Toxoplasma gondii, Legionella, Cryptosporidium, Isospora, and Papovavirus.
- Active evidence of infectious mononucleosis caused by Epstein-Barr virus (EBV) or cytomegalovirus (CMV) as determined by heterophil test (EBV) or cell culture (CMV).
- History of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, and severe gastric ulcer.
- Critical illness.
- Condition requiring hospitalization.
- Women of childbearing age are excluded.
- Hemophilia.
Prior Medication:
- Steroids.
- Cytotoxic immunosuppressive agents.
- Antiviral medicine.
Prior Treatment:
- Radiotherapy.
Patients who have unexplained immunodepression and are at risk of developing AIDS.
- Patients with prolonged generalized lymphadenopathy for 3 or more months (greater than 1 cm at two or more noncontiguous sites).
IV drug abuse.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002296
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002296
|United States, California
|Newport Pharmaceuticals International Inc
|Laguna Hills, California, United States, 92656
Sponsors and Collaborators
Newport Pharmaceuticals International
More Information
Keywords provided by NIH AIDS Clinical Trials Information Service:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 21, 2017
|ClinicalTrials.gov Identifier:
|NCT00002296 History of Changes
|Other Study ID Numbers:
|Study First Received:
|November 2, 1999
|Last Updated:
|June 23, 2005
Keywords provided by NIH AIDS Clinical Trials Information Service:
Immune Tolerance
Inosine Pranobex
Killer Cells
T-Lymphocytes, Helper-Inducer
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Additional relevant MeSH terms:
HIV Infections
Lymphatic Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Inosine Pranobex
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents
ClinicalTrials.gov processed this record on September 21, 2017